Innate Pharma (NASDAQ:IPHA) Earns Sell (E+) Rating from Weiss Ratings

Innate Pharma (NASDAQ:IPHA - Get Free Report)'s stock had its "sell (e+)" rating restated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently issued reports on IPHA. Leerink Partnrs cut shares of Innate Pharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 18th. Leerink Partners reaffirmed a "market perform" rating and issued a $2.00 target price (down from $10.00) on shares of Innate Pharma in a report on Thursday, September 18th. HC Wainwright cut shares of Innate Pharma from a "buy" rating to a "neutral" rating in a report on Thursday, September 18th. Finally, BTIG Research began coverage on shares of Innate Pharma in a research report on Monday, July 28th. They set a "buy" rating for the company. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $6.50.

Innate Pharma Stock Up 2.1%

IPHA stock opened at $1.99 on Wednesday. Innate Pharma has a twelve month low of $1.29 and a twelve month high of $3.51. The business has a 50 day moving average of $2.06 and a 200 day moving average of $2.01.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.